Pfizer Inc. Faces New Competitive Threat to Chantix; Sopharma's Generic Works Just as Well in Early Studies

Published: Sep 29, 2011

Pfizer is facing a threat to its top-selling smoking cessation drug Champix from the Bulgarian company that has long marketed the low-cost off-patent medicine from which it was derived.

A clinical study financed by British charities and medical funding agencies concludes that Tabex, sold by Sofia-based Sopharma, is promising because it is as effective and much cheaper than alternative products used by smokers seeking to quit, such as Champix.

Back to news